Steven L. Hoerter
CIK 1533451 · President and CEO · last filed 2026-06-26
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$2.31M
Companies
8
Total Filings
73
Lifetime Open-Market Net
-$9.16M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| CCCC | Director | — | $3.55 | — | $0 | 3 | 2026-06-26 |
| MBX | Director | 31,938 | $60.06 | $1.92M | $265.0K | 9 | 2026-06-05 |
| ORIC | Director | — | $11.91 | — | $0 | 6 | 2026-01-06 |
| Deciphera Pharmaceuticals, Inc. (DCPH) Delisted | President and CEO | 72,763 | $25.59 | $1.86M | -$1.33M | 21 | 2024-06-11 |
| CONSTELLATION PHARMACEUTICALS INC (CNST) Delisted | Director | — | $33.99 | — | $0 | 4 | 2021-06-04 |
| AGIO | Chief Commercial Officer | 10,941 | $35.99 | $393.8K | -$3.75M | 16 | 2019-03-05 |
| Ignyta, Inc. (RXDX) Delisted | Director | — | $199.92 | — | $0 | 2 | 2017-06-19 |
| Clovis Oncology, Inc. (CLVS) Delisted | See Remarks | 0 | $0.08 | $0 | -$4.34M | 9 | 2015-03-09 |
Recent Filings · Page 3 of 8
73 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2023-03-23 | Deciphera Pharmaceuticals, Inc. (DCPH) Delisted | Sell (S) | −7,500 | -$116.8K | EDGAR |
| 2023-02-16 | Deciphera Pharmaceuticals, Inc. (DCPH) Delisted | Mixed | −30,045 | -$480.7K | EDGAR |
| 2022-06-17 | ORIC | Grant (A) | — | $0 | EDGAR |
| 2022-03-23 | Deciphera Pharmaceuticals, Inc. (DCPH) Delisted | Tax (F) | −3,150 | -$28.7K | EDGAR |
| 2022-01-20 | Deciphera Pharmaceuticals, Inc. (DCPH) Delisted | Grant (A) | — | $0 | EDGAR |
| 2021-12-17 | Deciphera Pharmaceuticals, Inc. (DCPH) Delisted | Grant (A) | — | $0 | EDGAR |
| 2021-08-16 | ORIC | Grant (A) | — | $0 | EDGAR |
| 2021-07-23 | — | Disp (D) | — | $0 | |
| 2021-07-19 | — | Disp (D) | — | $0 | |
| 2021-06-04 | CONSTELLATION PHARMACEUTICALS INC (CNST) Delisted | Grant (A) | — | $0 | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.